• Explore /
  • Poster
  • / A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.

A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.

Abstract Poster

Authors

Ghassan Abou-Alfa

Ghassan K. Abou-Alfa

Memorial Sloan Kettering Cancer Center, New York, NY

Ghassan K. Abou-Alfa , Stephen Lam Chan , Junji Furuse , Peter R. Galle , Robin Kate Kelley , Shukui Qin , Jon Armstrong , Annie Darilay , Gordana Vlahovic , Alejandra Negro , Bruno Sangro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03298451

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS4144)

DOI

10.1200/JCO.2018.36.15_suppl.TPS4144

Abstract #

TPS4144

Poster Bd #

326b

Abstract Disclosures

Similar Posters

First Author: Ghassan K. Abou-Alfa

First Author: Jia Fan

First Author: Oxana V. Crysler

First Author: Claudia A.M. Fulgenzi